Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
54.93
+0.07 (+0.13%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi-Aventis S.A. ADR
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Why the dividend investor may take a look at NASDAQ:SNY.
February 14, 2024
Exploring SANOFI-ADR (NASDAQ:SNY)'s dividend characteristics.
Via
Chartmill
NASDAQ:SNY is an undervalued gem with solid fundamentals.
February 14, 2024
SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via
Chartmill
What's Going On Eli Lilly Stock Thursday?
February 08, 2024
Eli Lilly's impressive stock surge, better-than-expected Q4 results, and positive analyst reviews.
Via
Benzinga
Novo Nordisk To Up Production Capacity As Parent Buys Catalent
February 05, 2024
NVO stock rose after Novo Nordisk's parent, Novo Holdings, said it has agreed to buy contract manufacturer Catalent for $11.5 billion in cash.
Via
Investor's Business Daily
CytoReason's AI-Driven Disease Model Platform Trusted By 5 Top 10 Pharma Companies Harnesses Big Data To Speed Drug Discovery And Development
February 05, 2024
Click here to learn more about CytoReason and how to invest through OurCrowd.
Via
Benzinga
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets
February 03, 2024
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones.
Via
Talk Markets
Sanofi's Earnings Outlook
January 31, 2024
Via
Benzinga
Analyzing NASDAQ:SNY's Dividend Potential.
January 24, 2024
Balancing Dividends and Fundamentals: The Case of SANOFI-ADR (NASDAQ:SNY).
Via
Chartmill
Why NASDAQ:SNY is a Top Pick for Dividend Investors.
January 02, 2024
Analyzing SANOFI-ADR (NASDAQ:SNY)'s Dividend Potential.
Via
Chartmill
Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today?
February 02, 2024
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77.
Via
Benzinga
Sanofi (SNY) Q4 2023 Earnings Call Transcript
February 01, 2024
SNY earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 01, 2024
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.
Via
Benzinga
French Pharma Giant Sanofi's Q4 Earnings Hit By Aubagio Generic Competition, Helped By Flagship Eczema And Newly Launched Hemophilia Drugs
February 01, 2024
Sanofi reports Q4 operating income of €2.6B, down 5.2%. Revenues rise 1.8% to €10.92B, Specialty Care grows 13.7%, Dupixent sales surge.
Via
Benzinga
Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't.
February 01, 2024
The company missed total sales and earnings expectations.
Via
Investor's Business Daily
Nasdaq Futures Rebound As Traders Eye Apple, Meta, Amazon Earnings: Analyst Flags 'January Barometer' That Bodes Well For The Year
February 01, 2024
After ending January with modest gains, the major averages now look to earnings catalysts to drive momentum, with futures higher in first trading session of February.
Via
Benzinga
MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
February 01, 2024
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 90 points on Thursday.
Via
Benzinga
Earnings Scheduled For February 1, 2024
February 01, 2024
Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on...
Via
Benzinga
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Regeneron/Sanofi's Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation
January 26, 2024
FDA approves Dupixent (dupilumab) by Regeneron/Sanofi for pediatric eosinophilic esophagitis treatment. Breakthrough treatment for young patients.
Via
Benzinga
Exposures
Product Safety
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
January 25, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx
January 23, 2024
The company is buying Inhibrx, which is working on a treatment for alpha-1 antitrypsin deficiency.
Via
Investor's Business Daily
French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B
January 23, 2024
Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected...
Via
Benzinga
Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project
January 23, 2024
Following the acquisition, New Inhibrx will continue to operate under the "Inhibrx" name, with Mark Lappe as Chairman and CEO.
Via
Benzinga
Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
January 22, 2024
HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape.
Via
Benzinga
Time to buy these 3 healthcare companies that raised revenue guidance?
January 16, 2024
The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance.
Via
MarketBeat
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
January 12, 2024
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.
Via
Investor's Business Daily
Sanofi's Olympic Endeavor: Leap Into Olympic Sponsorship Signals Cultural Transformation
January 10, 2024
French pharmaceutical giant Sanofi SA (NASDAQ: SNY) is making an unconventional stride by sponsoring the 2024 Olympic Games in Paris in an effort to rejuvenate the company's image, attract a younger...
Via
Benzinga
Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering
January 05, 2024
Shares soared and then tumbled Friday after the company offered $275 million in public shares.
Via
Investor's Business Daily
More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024
January 04, 2024
More than 140 brands of drugs are going to see their prices hiked heading into the new year
Via
Talk Markets
China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants
January 02, 2024
Tuesday, China's National Medical Products Administration approved AstraZeneca Plc (NASD
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.